Mesoblast Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Mesoblast
MESO Stock  USD 17.25  0.71  3.95%   
Mesoblast's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mesoblast's valuation are provided below:
Gross Profit
-22.7 M
Market Capitalization
1.9 B
Enterprise Value Revenue
123.2524
Revenue
17.2 M
Earnings Share
(0.85)
We have found one hundred twenty available fundamental ratios for Mesoblast, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Mesoblast's last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 31st of January 2026, Market Cap is likely to drop to about 1.3 B. In addition to that, Enterprise Value is likely to drop to about 1.2 B

Mesoblast Total Revenue

15.39 Million

Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.7 M, Interest Expense of 27.7 M or Selling General Administrative of 20.8 M, as well as many indicators such as Price To Sales Ratio of 79.18, Dividend Yield of 0.0 or PTB Ratio of 2.28. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Build AI portfolio with Mesoblast Stock
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Mesoblast Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets596.4 M902.4 M705.3 M
Pretty Stable
Other Current Liabilities32.3 M30.7 M17 M
Slightly volatile
Total Current Liabilities123.9 M118 M60.8 M
Slightly volatile
Total Stockholder Equity430.9 M687.1 M512.2 M
Slightly volatile
Property Plant And Equipment Net3.8 M6.7 M4.8 M
Slightly volatile
Accounts Payable15 M21.9 M18.4 M
Pretty Stable
Cash194.6 M185.3 M83.4 M
Slightly volatile
Non Current Assets Total474.8 M667.4 M568.3 M
Pretty Stable
Cash And Short Term Investments194.6 M185.3 M83.4 M
Slightly volatile
Net Receivables18 M17.1 M9 M
Slightly volatile
Common Stock Shares Outstanding69.5 M138.9 M71.3 M
Slightly volatile
Liabilities And Stockholders Equity596.4 M902.4 M705.3 M
Pretty Stable
Other Current Assets5.2 M5.5 M58 M
Slightly volatile
Other Stockholder Equity80.3 M84.5 M343.8 M
Pretty Stable
Total Liabilities165.5 M215.3 M193.1 M
Pretty Stable
Property Plant And Equipment Gross29 M27.6 M12.1 M
Slightly volatile
Total Current Assets121.6 M235 M136.9 M
Very volatile
Accumulated Other Comprehensive Income120.1 M114.4 M67.7 M
Slightly volatile
Intangible Assets358.9 M503 M432.1 M
Pretty Stable
Non Current Liabilities Total116.4 M76.2 M135.5 M
Slightly volatile
Good Will147.7 M154.6 M136.2 M
Slightly volatile
Non Currrent Assets Other1.7 M1.2 M2 M
Pretty Stable
Short Term Debt68.6 M65.4 M34.5 M
Slightly volatile
Common Stock1.1 B1.7 B981 M
Slightly volatile
Common Stock Total Equity939.2 M1.3 B936.6 M
Slightly volatile
Short Term Investments2.6 M2.9 M3.1 M
Slightly volatile
Other Liabilities16.3 M17.2 M73.5 M
Slightly volatile
Other Assets2 M2.1 M2.5 M
Slightly volatile
Property Plant Equipment6 M7.5 M5.5 M
Slightly volatile
Deferred Long Term Liabilities75.7 M44.4 M87.4 M
Slightly volatile
Long Term Investments1.5 M1.2 M1.9 M
Slightly volatile
Net Invested Capital674.3 M827.2 M595.3 M
Slightly volatile
Net Working Capital122.8 M117 M46.9 M
Slightly volatile
Short and Long Term Debt Total112.2 M147.4 M87.7 M
Slightly volatile
Long Term Debt80.8 M77.9 M68.3 M
Slightly volatile
Long Term Debt Total69.7 M77.4 M64.3 M
Slightly volatile
Short and Long Term Debt51.2 M48.7 M44.3 M
Slightly volatile
Capital Stock1.3 B1.7 B1.1 B
Slightly volatile
Capital Lease Obligations6.7 M5.6 M8.9 M
Slightly volatile

Mesoblast Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.7 M7.4 M3.2 M
Slightly volatile
Selling General Administrative20.8 M26.7 M24.4 M
Pretty Stable
Total Revenue15.4 M15.5 M18.1 M
Slightly volatile
Other Operating Expenses73.7 M91.6 M88 M
Pretty Stable
Research Development37.9 M40 M44.4 M
Pretty Stable
Total Operating Expenses71.3 M85.7 M84.8 M
Very volatile
Selling And Marketing Expenses17.8 M14.5 M21.5 M
Pretty Stable
Cost Of Revenue5.6 M5.9 M34.1 M
Very volatile
Non Recurring49.5 M55.7 M60.8 M
Slightly volatile
Reconciled Depreciation4.3 M7.4 M3.8 M
Slightly volatile
Interest Income4.3 M4.1 M1.1 M
Slightly volatile

Mesoblast Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.7 M25.4 M10.1 M
Slightly volatile
Depreciation7.7 M7.4 M3.3 M
Slightly volatile
Capital Expenditures624.1 K657 K3.3 M
Slightly volatile
End Period Cash Flow108 M185.8 M118.2 M
Pretty Stable
Begin Period Cash Flow102.6 M72.4 M115.1 M
Slightly volatile
Sale Purchase Of Stock45.8 M34.8 M30.5 M
Slightly volatile
Issuance Of Capital Stock93.8 M185.4 M65.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio79.1883.3596.4936
Slightly volatile
PTB Ratio2.282.42.5283
Slightly volatile
Days Sales Outstanding345363266
Slightly volatile
Book Value Per Share0.530.470.7992
Slightly volatile
Average Payables1.3 M1.2 M1.1 M
Very volatile
Stock Based Compensation To Revenue1.41.480.7402
Slightly volatile
Capex To Depreciation0.120.135.1771
Slightly volatile
PB Ratio2.282.42.5283
Slightly volatile
EV To Sales77.0881.1493.8734
Slightly volatile
Payables Turnover0.230.241.9119
Pretty Stable
Sales General And Administrative To Revenue1.471.552.2535
Pretty Stable
Research And Ddevelopement To Revenue2.212.334.0218
Very volatile
Capex To Revenue0.04640.04880.2334
Slightly volatile
Cash Per Share0.0880.130.109
Very volatile
Days Payables Outstanding1.3 K1.2 K500
Slightly volatile
Income Quality0.420.442.0507
Pretty Stable
Intangibles To Total Assets0.460.660.7323
Pretty Stable
Current Ratio2.182.292.9484
Slightly volatile
Receivables Turnover1.261.33141
Slightly volatile
Shareholders Equity Per Share0.530.470.7992
Slightly volatile
Debt To Equity0.150.190.1559
Slightly volatile
Capex Per Share7.0E-47.0E-40.0059
Slightly volatile
Average Receivables6 M5.7 M6 M
Slightly volatile
Revenue Per Share0.01650.01730.0305
Slightly volatile
Interest Debt Per Share0.07290.120.1056
Slightly volatile
Debt To Assets0.120.150.1197
Slightly volatile
Graham Number1.531.721.8741
Slightly volatile
Price Book Value Ratio2.282.42.5283
Slightly volatile
Days Of Payables Outstanding1.3 K1.2 K500
Slightly volatile
Ebt Per Ebit1.321.881.2218
Slightly volatile
Company Equity Multiplier1.051.181.3336
Slightly volatile
Long Term Debt To Capitalization0.0960.09170.1092
Slightly volatile
Total Debt To Capitalization0.130.160.1333
Slightly volatile
Debt Equity Ratio0.150.190.1559
Slightly volatile
Quick Ratio1.942.042.1414
Slightly volatile
Net Income Per E B T0.730.90.845
Very volatile
Cash Ratio1.721.811.6812
Slightly volatile
Days Of Sales Outstanding345363266
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.171.1357
Slightly volatile
Price To Book Ratio2.282.42.5283
Slightly volatile
Fixed Asset Turnover3.233.47.3887
Slightly volatile
Debt Ratio0.120.150.1197
Slightly volatile
Price Sales Ratio79.1883.3596.4936
Slightly volatile
Asset Turnover0.04530.02520.027
Pretty Stable
Price Fair Value2.282.42.5283
Slightly volatile

Mesoblast Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B1.4 B1.1 B
Slightly volatile
Enterprise Value1.2 B1.4 B1.1 B
Slightly volatile

Mesoblast Fundamental Market Drivers

Forward Price Earnings454.5455
Cash And Short Term Investments161.2 M

Mesoblast Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
23rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as revenue or net income, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.8 M6 M
Total Revenue15.5 M15.4 M
Cost Of Revenue5.9 M5.6 M
Stock Based Compensation To Revenue 1.48  1.40 
Sales General And Administrative To Revenue 1.55  1.47 
Research And Ddevelopement To Revenue 2.33  2.21 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(3.27)(3.43)

Pair Trading with Mesoblast

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Moving against Mesoblast Stock

  0.86ACLX ArcellxPairCorr
  0.69RANI Rani TherapeuticsPairCorr
  0.57EVGN EvogenePairCorr
  0.55CRBP Corbus PharmaceuticalsPairCorr
  0.52APLT Applied TherapeuticsPairCorr
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
How To Invest In Mesoblast
Details
Is Mesoblast Stock a good investment?
Details
What is Mesoblast's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could Mesoblast diversify its offerings? Factors like these will boost the valuation of Mesoblast. Expected growth trajectory for Mesoblast significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mesoblast data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.85)
Revenue Per Share
0.14
Quarterly Revenue Growth
4.586
Return On Assets
(0.05)
Return On Equity
(0.19)
Investors evaluate Mesoblast using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mesoblast's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mesoblast's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Mesoblast's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesoblast represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mesoblast's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY